PT  - JOURNAL ARTICLE
AU  - Marc A. Judson
AU  - Robert P. Baughman
AU  - Ulrich Costabel
AU  - Marjolein Drent
AU  - Kevin F. Gibson
AU  - Ganesh Raghu
AU  - Hidenobu Shigemitsu
AU  - Joseph B. Barney
AU  - Daniel A. Culver
AU  - Nabeel Y. Hamzeh
AU  - Marlies S. Wijsenbeek
AU  - Carlo Albera
AU  - Isham Huizar
AU  - Prasheen Agarwal
AU  - Carrie Brodmerkel
AU  - Rosemary Watt
AU  - Elliot S. Barnathan
TI  - Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis
AID  - 10.1183/09031936.00000914
DP  - 2014 Jan 01
TA  - European Respiratory Journal
PG  - erj00009-2014
4099  - http://erj.ersjournals.com/content/early/2014/07/17/09031936.00000914.short
4100  - http://erj.ersjournals.com/content/early/2014/07/17/09031936.00000914.full
AB  - Sarcoidosis is characterised by non-caseating granulomas that secrete pro-inflammatory cytokines, including interleukin (IL)-12, IL-23, and tumour necrosis factor (TNF)-α. Ustekinumab and golimumab are monoclonal antibodies that specifically inhibit IL-12/IL-23 and TNF-α, respectively. Patients with chronic pulmonary sarcoidosis (lung group) and/or skin sarcoidosis (skin group) received either 180 mg ustekinumab at week 0 followed by 90 mg every 8 weeks, 200 mg golimumab at week 0 followed by 100 mg every 4 weeks, or placebo. Patients underwent corticosteroid tapering between weeks 16 and 28. The primary end-point was week 16 change in percentage predicted forced vital capacity (ΔFVC % pred) in the lung group. Major secondary end-points were: week 28 for ΔFVC % pred, 6-min walking distance, St George's Respiratory Questionnaire (lung group), and Skin Physician Global Assessment response (skin group). At week 16, no significant differences were observed in ΔFVC % pred with ustekinumab (-0.15, p = 0.13) or golimumab (1.15, p = 0.54) compared with placebo (2.02). At week 28, there were no significant improvements in the major secondary end-points, although a nonsignificant numerically greater Skin Physician Global Assessment response was observed following golimumab treatment (53%) when compared with the placebo (30%). Serious adverse events were similar in all treatment groups. Although treatment was well tolerated, neither ustekinumab nor golimumab demonstrated efficacy in pulmonary sarcoidosis. However, trends towards improvement were observed with golimumab in some dermatological end-points. Neither ustekinumab nor golimumab demonstrated efficacy for the treatment of patients with pulmonary sarcoidosis http://ow.ly/yaLt6